{"id":"https://openalex.org/W3156916747","doi":"https://doi.org/10.2147/ceor.s302097","title":"Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain","display_name":"Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain","publication_year":2021,"publication_date":"2021-04-01","ids":{"openalex":"https://openalex.org/W3156916747","doi":"https://doi.org/10.2147/ceor.s302097","mag":"3156916747","pmid":"https://pubmed.ncbi.nlm.nih.gov/33911887","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/8075179"},"language":"en","primary_location":{"id":"doi:10.2147/ceor.s302097","doi":"https://doi.org/10.2147/ceor.s302097","is_oa":true,"landing_page_url":"https://doi.org/10.2147/ceor.s302097","pdf_url":"https://www.dovepress.com/getfile.php?fileID=68776","source":{"id":"https://openalex.org/S2736382696","display_name":"ClinicoEconomics and Outcomes Research","issn_l":"1178-6981","issn":["1178-6981"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","dongbi-c","jufo-1","ki-jl-1","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320348","host_organization_name":"Dove Medical Press","host_organization_lineage":["https://openalex.org/P4310320348","https://openalex.org/P4310320547"],"host_organization_lineage_names":["Dove Medical Press","Taylor & Francis"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"ClinicoEconomics and Outcomes Research","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.dovepress.com/getfile.php?fileID=68776","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5028204670","display_name":"Mar\u00eda Mareque","orcid":"https://orcid.org/0000-0001-8438-4977","observed_orcids":["https://orcid.org/0000-0001-8438-4977"]},"institutions":[{"id":"https://openalex.org/I4210165298","display_name":"Pharmacoeconomics and Health Outcomes Research Iberia (Spain)","ror":"https://ror.org/05sb05859","country_code":"ES","type":"company","lineage":["https://openalex.org/I4210165298"]}],"countries":["ES"],"is_corresponding":true,"raw_author_name":"Maria Mareque","raw_affiliation_strings":["Pharmacoeconomics & Outcomes Research Iberia (PORIB), Madrid, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmacoeconomics & Outcomes Research Iberia (PORIB), Madrid, Spain","institution_ids":["https://openalex.org/I4210165298"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003682435","display_name":"Pau Montesinos","orcid":"https://orcid.org/0000-0002-3275-5593","observed_orcids":["https://orcid.org/0000-0002-3275-5593"]},"institutions":[{"id":"https://openalex.org/I3019010403","display_name":"Hospital Universitari i Polit\u00e8cnic La Fe","ror":"https://ror.org/01ar2v535","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I3019010403","https://openalex.org/I4210166036"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Pau Montesinos","raw_affiliation_strings":["Hospital Universitario La Fe, Valencia, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hospital Universitario La Fe, Valencia, Spain","institution_ids":["https://openalex.org/I3019010403"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088766736","display_name":"Patricia Font","orcid":"https://orcid.org/0000-0002-9738-4930","observed_orcids":["https://orcid.org/0000-0002-9738-4930"]},"institutions":[{"id":"https://openalex.org/I2960094004","display_name":"Hospital General Universitario Gregorio Mara\u00f1\u00f3n","ror":"https://ror.org/0111es613","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I2960094004","https://openalex.org/I4210139293"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Patricia Font","raw_affiliation_strings":["Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain","institution_ids":["https://openalex.org/I2960094004"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013537484","display_name":"Jos\u00e9 Mar\u00eda Guinea de Castro","orcid":"https://orcid.org/0000-0003-3285-0539","observed_orcids":["https://orcid.org/0000-0003-3285-0539"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jos\u00e9 Mar\u00eda Guinea","raw_affiliation_strings":["Organizaci\u00f3n Sanitaria Integrada Araba, Pa\u00eds Vasco, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Organizaci\u00f3n Sanitaria Integrada Araba, Pa\u00eds Vasco, Spain","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011343192","display_name":"Adolfo de la Fuente","orcid":"https://orcid.org/0000-0002-1324-5555","observed_orcids":["https://orcid.org/0000-0002-1324-5555"]},"institutions":[{"id":"https://openalex.org/I4210158781","display_name":"MD Anderson Cancer Center Madrid","ror":"https://ror.org/05mq65528","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210158781"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Adolfo de la Fuente","raw_affiliation_strings":["Hospital MD Anderson, Madrid, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hospital MD Anderson, Madrid, Spain","institution_ids":["https://openalex.org/I4210158781"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100617616","display_name":"Javier Soto","orcid":"https://orcid.org/0000-0001-7726-9030","observed_orcids":["https://orcid.org/0000-0001-7726-9030"]},"institutions":[{"id":"https://openalex.org/I4210138890","display_name":"Pfizer (Spain)","ror":"https://ror.org/03x2xt559","country_code":"ES","type":"company","lineage":["https://openalex.org/I180857899","https://openalex.org/I4210138890"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Javier Soto","raw_affiliation_strings":["Pfizer, Madrid, Spain"],"raw_orcid":"https://orcid.org/0000-0001-7726-9030","affiliations":[{"raw_affiliation_string":"Pfizer, Madrid, Spain","institution_ids":["https://openalex.org/I4210138890"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069146288","display_name":"Itziar Oyag\u00fcez","orcid":"https://orcid.org/0000-0002-3047-6152","observed_orcids":["https://orcid.org/0000-0002-3047-6152"]},"institutions":[{"id":"https://openalex.org/I4210165298","display_name":"Pharmacoeconomics and Health Outcomes Research Iberia (Spain)","ror":"https://ror.org/05sb05859","country_code":"ES","type":"company","lineage":["https://openalex.org/I4210165298"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Itziar Oyag\u00fcez","raw_affiliation_strings":["Pharmacoeconomics & Outcomes Research Iberia (PORIB), Madrid, Spain"],"raw_orcid":"https://orcid.org/0000-0002-3047-6152","affiliations":[{"raw_affiliation_string":"Pharmacoeconomics & Outcomes Research Iberia (PORIB), Madrid, Spain","institution_ids":["https://openalex.org/I4210165298"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005463047","display_name":"James Brockbank","orcid":"https://orcid.org/0000-0002-5349-6017","observed_orcids":["https://orcid.org/0000-0002-5349-6017"]},"institutions":[{"id":"https://openalex.org/I4210120329","display_name":"RTI Health Solutions","ror":"https://ror.org/032nh7f71","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I137902535","https://openalex.org/I170897317","https://openalex.org/I180297670","https://openalex.org/I4210120329"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"James Brockbank","raw_affiliation_strings":["RTI Health Solutions, Manchester, UK"],"raw_orcid":"https://orcid.org/0000-0002-5349-6017","affiliations":[{"raw_affiliation_string":"RTI Health Solutions, Manchester, UK","institution_ids":["https://openalex.org/I4210120329"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007747582","display_name":"Tamara Iglesias","orcid":"https://orcid.org/0000-0002-1623-1677","observed_orcids":["https://orcid.org/0000-0002-1623-1677"]},"institutions":[{"id":"https://openalex.org/I4210138890","display_name":"Pfizer (Spain)","ror":"https://ror.org/03x2xt559","country_code":"ES","type":"company","lineage":["https://openalex.org/I180857899","https://openalex.org/I4210138890"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Tamara Iglesias","raw_affiliation_strings":["Pfizer, Madrid, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer, Madrid, Spain","institution_ids":["https://openalex.org/I4210138890"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015913154","display_name":"Julia Llinares","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210138890","display_name":"Pfizer (Spain)","ror":"https://ror.org/03x2xt559","country_code":"ES","type":"company","lineage":["https://openalex.org/I180857899","https://openalex.org/I4210138890"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Julia Llinares","raw_affiliation_strings":["Pfizer, Madrid, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer, Madrid, Spain","institution_ids":["https://openalex.org/I4210138890"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5025894116","display_name":"Jorge Sierra","orcid":"https://orcid.org/0000-0002-7966-0356","observed_orcids":["https://orcid.org/0000-0002-7966-0356","https://orcid.org/0000-0001-7546-326X"]},"institutions":[{"id":"https://openalex.org/I2801795740","display_name":"Hospital de Sant Pau","ror":"https://ror.org/059n1d175","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I2801795740"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Jorge Sierra","raw_affiliation_strings":["Hospital Universitario de La Santa Creu i Sant Pau, Barcelona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hospital Universitario de La Santa Creu i Sant Pau, Barcelona, Spain","institution_ids":["https://openalex.org/I2801795740"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":7,"corresponding_author_ids":["https://openalex.org/A5028204670"],"corresponding_institution_ids":["https://openalex.org/I4210165298"],"apc_list":{"value":2320,"currency":"USD","value_usd":2320},"apc_paid":{"value":2320,"currency":"USD","value_usd":2320},"fwci":1.4265,"has_fulltext":true,"cited_by_count":9,"citation_normalized_percentile":{"value":0.85081843,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":96},"biblio":{"volume":"Volume 13","issue":null,"first_page":"263","last_page":"277"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.9189000129699707,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.9189000129699707,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.05400000140070915,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12708","display_name":"Economic and Financial Impacts of Cancer","score":0.018400000408291817,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/gemtuzumab-ozogamicin","display_name":"gemtuzumab ozogamicin","score":1.0},{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":0.9950000047683716},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.8560000061988831},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.953000009059906},{"id":"https://openalex.org/keywords/incremental-cost-utility-ratio","display_name":"incremental cost-utility ratio","score":0.9179999828338623},{"id":"https://openalex.org/keywords/state-transition-model","display_name":"state transition model","score":0.6859999895095825},{"id":"https://openalex.org/keywords/quality-adjusted-life-years","display_name":"quality-adjusted life years","score":0.8759999871253967},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.7110000252723694},{"id":"https://openalex.org/keywords/hematopoietic-stem-cell-transplantation","display_name":"hematopoietic stem cell transplantation","score":0.7519999742507935},{"id":"https://openalex.org/keywords/spanish-health-system","display_name":"Spanish health system","score":0.503000020980835}],"concepts":[{"id":"https://openalex.org/C2778623314","wikidata":"https://www.wikidata.org/wiki/Q412685","display_name":"Gemtuzumab ozogamicin","level":5,"score":0.8863558769226074},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8838387727737427},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.6237330436706543},{"id":"https://openalex.org/C64332521","wikidata":"https://www.wikidata.org/wiki/Q614165","display_name":"Quality-adjusted life year","level":3,"score":0.5310355424880981},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4560035467147827},{"id":"https://openalex.org/C184834754","wikidata":"https://www.wikidata.org/wiki/Q358564","display_name":"Cost\u2013utility analysis","level":3,"score":0.45054495334625244},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.40981531143188477},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3743327260017395},{"id":"https://openalex.org/C3019080777","wikidata":"https://www.wikidata.org/wiki/Q1754768","display_name":"Cost effectiveness","level":2,"score":0.3610043525695801},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.33240586519241333},{"id":"https://openalex.org/C28328180","wikidata":"https://www.wikidata.org/wiki/Q48196","display_name":"Stem cell","level":2,"score":0.17190450429916382},{"id":"https://openalex.org/C10205521","wikidata":"https://www.wikidata.org/wiki/Q4035578","display_name":"CD34","level":3,"score":0.0724790096282959},{"id":"https://openalex.org/C176290653","wikidata":"https://www.wikidata.org/wiki/Q21114013","display_name":"CD33","level":4,"score":0.0},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0},{"id":"https://openalex.org/C112930515","wikidata":"https://www.wikidata.org/wiki/Q4389547","display_name":"Risk analysis (engineering)","level":1,"score":0.0},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.0}],"mesh":[],"locations_count":6,"locations":[{"id":"doi:10.2147/ceor.s302097","doi":"https://doi.org/10.2147/ceor.s302097","is_oa":true,"landing_page_url":"https://doi.org/10.2147/ceor.s302097","pdf_url":"https://www.dovepress.com/getfile.php?fileID=68776","source":{"id":"https://openalex.org/S2736382696","display_name":"ClinicoEconomics and Outcomes Research","issn_l":"1178-6981","issn":["1178-6981"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","dongbi-c","jufo-1","ki-jl-1","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320348","host_organization_name":"Dove Medical Press","host_organization_lineage":["https://openalex.org/P4310320348","https://openalex.org/P4310320547"],"host_organization_lineage_names":["Dove Medical Press","Taylor & Francis"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"ClinicoEconomics and Outcomes Research","raw_type":"journal-article"},{"id":"pmid:33911887","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/33911887","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"ClinicoEconomics and outcomes research : CEOR","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:8075179","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8075179/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinicoecon Outcomes Res","raw_type":"Text"},{"id":"pmh:oai:ddd.uab.cat:270187","doi":null,"is_oa":true,"landing_page_url":"https://ddd.uab.cat/record/270187","pdf_url":"https://ddd.uab.cat/pub/artpub/2021/270187/270187.pdf","source":{"id":"https://openalex.org/S4306400380","display_name":"Dip\u00f2sit Digital de Documents de la UAB (Universitat Aut\u00f2noma de Barcelona)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I123044942","host_organization_name":"Universitat Aut\u00f2noma de Barcelona","host_organization_lineage":["https://openalex.org/I123044942"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Article"},{"id":"pmh:oai:doaj.org/article:e8d13246c5bb4958b110035d96a427b0","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/e8d13246c5bb4958b110035d96a427b0","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"ClinicoEconomics and Outcomes Research, Vol Volume 13, Pp 263-277 (2021)","raw_type":"article"},{"id":"pmh:oai:dovepress.com/64194","doi":null,"is_oa":true,"landing_page_url":"https://www.dovepress.com/cost-effectiveness-analysis-of-gemtuzumab-ozogamicin-for-first-line-tr-peer-reviewed-fulltext-article-CEOR","pdf_url":null,"source":{"id":"https://openalex.org/S4306401012","display_name":"Dove Medical Press (Taylor and Francis Group)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":{"id":"doi:10.2147/ceor.s302097","doi":"https://doi.org/10.2147/ceor.s302097","is_oa":true,"landing_page_url":"https://doi.org/10.2147/ceor.s302097","pdf_url":"https://www.dovepress.com/getfile.php?fileID=68776","source":{"id":"https://openalex.org/S2736382696","display_name":"ClinicoEconomics and Outcomes Research","issn_l":"1178-6981","issn":["1178-6981"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","dongbi-c","jufo-1","ki-jl-1","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320348","host_organization_name":"Dove Medical Press","host_organization_lineage":["https://openalex.org/P4310320348","https://openalex.org/P4310320547"],"host_organization_lineage_names":["Dove Medical Press","Taylor & Francis"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"ClinicoEconomics and Outcomes Research","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9537000060081482,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W3156916747.pdf","grobid_xml":"https://content.openalex.org/works/W3156916747.grobid-xml"},"referenced_works_count":32,"referenced_works":["https://openalex.org/W1536517071","https://openalex.org/W1557245552","https://openalex.org/W1966327132","https://openalex.org/W1977628820","https://openalex.org/W1989203171","https://openalex.org/W1996383959","https://openalex.org/W2025338891","https://openalex.org/W2040901964","https://openalex.org/W2065406906","https://openalex.org/W2087334241","https://openalex.org/W2122317738","https://openalex.org/W2129785424","https://openalex.org/W2137881702","https://openalex.org/W2143835472","https://openalex.org/W2146862320","https://openalex.org/W2147222462","https://openalex.org/W2172277773","https://openalex.org/W2237124828","https://openalex.org/W2339650126","https://openalex.org/W2461928138","https://openalex.org/W2559537906","https://openalex.org/W2725930552","https://openalex.org/W2886748809","https://openalex.org/W2890626177","https://openalex.org/W2931981435","https://openalex.org/W2940785484","https://openalex.org/W2986834274","https://openalex.org/W2989842817","https://openalex.org/W2997679387","https://openalex.org/W3015554812","https://openalex.org/W3127939395","https://openalex.org/W4210975056"],"related_works":["https://openalex.org/W3175394789","https://openalex.org/W4316345198","https://openalex.org/W2996046590","https://openalex.org/W6958494359","https://openalex.org/W3111449997","https://openalex.org/W3143850699","https://openalex.org/W3108979464","https://openalex.org/W2042399679","https://openalex.org/W3193528733","https://openalex.org/W3154383630"],"abstract_inverted_index":{"Objective:":[0],"To":[1],"assess":[2],"the":[3,46,73,91,104,108],"incremental":[4],"cost\u2013utility":[5],"ratio":[6],"(ICUR)":[7],"of":[8,14,22,54,196],"gemtuzumab":[9,207],"ozogamicin":[10],"(GO)":[11],"+":[12,187],"standard":[13],"care":[15],"(SOC)":[16],"vs":[17,160,167,173],"SOC":[18,83,188],"alone":[19],"for":[20,103,194,214],"treatment":[21,195],"patients":[23,59,197],"with":[24,39,60,117,171,198],"de":[25,199],"novo":[26,200],"AML":[27,58,201],"from":[28,140],"a":[29,191],"Spanish":[30],"Health":[31],"Service":[32],"perspective.":[33],"Methods:":[34],"A":[35],"cohort":[36,109],"state-transition":[37],"model,":[38],"12":[40],"health-states,":[41],"was":[42,69,84,177],"used":[43,94],"to":[44,86],"estimate":[45],"lifetime":[47],"accumulated":[48],"cost":[49,122],"and":[50,63,89,113,133,150,163],"benefits":[51],"in":[52,57,95,110,202],"terms":[53],"quality-adjusted-life-years":[55],"(QALYs)":[56],"favourable,":[61],"intermediate,":[62],"unknown":[64],"cytogenetic":[65],"profiles.":[66],"Patient":[67],"profile":[68],"defined":[70,79],"based":[71],"on":[72],"ALFA-0701":[74],"trial.":[75],"Therapeutic":[76],"regimens":[77],"were":[78,98,138,145,152,169],"by":[80,100,107,147],"5":[81],"haematologists.":[82],"assumed":[85],"be":[87,190],"idarubicin":[88],"cytarabine,":[90],"combination":[92],"most":[93],"Spain.":[96],"QALYs":[97,165],"estimated":[99],"applying":[101],"utilities":[102],"time":[105],"spent":[106],"each":[111],"health-state":[112],"utility":[114],"decrements":[115],"associated":[116],"adverse":[118],"events":[119],"(AE).":[120],"Total":[121],"(\u20ac,2020)":[123],"included":[124],"drug-acquisition,":[125],"hematologic":[126],"stem-cell":[127],"transplantation,":[128],"disease":[129],"management,":[130],"AE":[131],"management":[132],"end-of-life":[134],"costs.":[135],"Unit":[136],"costs":[137],"derived":[139],"local":[141],"databases.":[142],"All":[143],"parameters":[144],"validated":[146],"haematologist.":[148],"Costs":[149],"outcomes":[151],"discounted":[153],"(3%/year).":[154],"Results:":[155],"Higher":[156],"cost/patient":[157],"(\u20ac":[158],"177,618":[159],"\u20ac":[161,178],"151,434)":[162],"greater":[164],"(5,70":[166],"4,62)":[168],"obtained":[170],"GO+SOC":[172],"SOC.":[174],"The":[175],"ICUR":[176],"24,203/QALY":[179],"gained.":[180],"Conclusion:":[181],"This":[182],"simulation":[183],"suggests":[184],"that":[185],"GO":[186],"could":[189],"cost-effective":[192],"option":[193],"first":[203],"line.":[204],"Keywords:":[205],"cost-effectiveness,":[206],"ozogamicin,":[208],"acute":[209],"myeloid":[210],"leukaemia,":[211],"Spain":[212],"Corrigendum":[213],"this":[215],"paper":[216],"has":[217],"been":[218],"published":[219]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":2}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2021-04-26T00:00:00"}